Intravenous alteplase eligibility is a time-critical stroke emergency. Intravenous alteplase eligibility is a time-critical reperfusion decision in acute ischemic stroke. The exam framework is simple but strict: confirm an ischemic disabling deficit, determine time/last-known-well, exclude hemorrhage on CT, ensure BP and bleeding risk are acceptable, and treat promptly without unnecessary delay. The main feared complication is symptomatic intracranial hemorrhage, and thrombectomy assessment should occur in parallel when large-vessel occlusion is suspected.
What Is Intravenous alteplase eligibility?
Intravenous alteplase eligibility means a patient with suspected acute ischemic stroke has a clinical and imaging profile in which the expected benefit of IV alteplase outweighs the bleeding risk within the approved treatment framework.
Why Intravenous alteplase eligibility Matters
- Define the role of intravenous alteplase in acute ischemic stroke.
- Apply a practical eligibility screen using onset time, disabling deficit, CT findings, BP, glucose, and bleeding risk.
- Recognize common contraindications, complications, and exam traps.
Definition and Diagnostic Criteria
Intravenous alteplase eligibility means a patient with suspected acute ischemic stroke has a clinical and imaging profile in which the expected benefit of IV alteplase outweighs the bleeding risk within the approved treatment framework.
Important Cut-offs
- Standard time window is classically within 4.5 hours from onset / last-known-well in eligible patients.
- Blood pressure should be controlled to thrombolysis-safe protocol thresholds before treatment.
- Severe hypoglycaemia can mimic stroke and must be corrected/excluded.
- Platelets, anticoagulant status, and CT findings may change eligibility.
- Patients with disabling deficit are prioritized; non-disabling minor symptoms require more caution.
For a formal framework, see the KDIGO guidance.
Classification and Staging
Practical eligibility groups
- Clearly eligible: disabling ischemic deficit, within window, CT excludes bleed, no major contraindication
- Potentially eligible after correction: BP initially too high but controllable, glucose abnormal but correctable, incomplete but rapidly clarifiable history
- Ineligible / high risk: hemorrhage, major active bleeding risk, certain anticoagulation/coagulation problems, very late untreated window under standard criteria
Common Causes of Intravenous alteplase eligibility
This note is about treatment selection, not disease causation; however alteplase is typically considered in:
- Cardioembolic stroke
- Large-artery thromboembolic stroke
- Some lacunar and other non-hemorrhagic ischemic strokes if disabling
If you want to compare this with other stroke medicine content, you can also browse the Stroke Medicine category.
Intravenous alteplase eligibility Symptoms and Clinical Features
Features favoring treatment consideration
- Sudden focal neurological deficit consistent with stroke
- Persistent deficit at evaluation
- Clinically disabling symptoms such as hemiparesis, aphasia, hemianopia, severe dysarthria, brainstem syndrome, or disabling ataxia
- Last-known-well within accepted thrombolysis window
Situations demanding caution
- Very mild and clearly non-disabling symptoms
- Seizure at onset with uncertainty whether deficit is post-ictal rather than ischemic
- Rapidly improving symptoms but residual disabling deficit remains
- High bleeding-risk history
Diagnosis and Evaluation of Intravenous alteplase eligibility: A Practical Approach
flowchart TD
A[Suspected acute ischemic stroke] --> B[ABC + glucose + last-known-well]
B --> C[Urgent non-contrast CT head]
C --> D{Hemorrhage excluded?}
D -->|No| E[Not eligible for alteplase]
D -->|Yes| F[Assess disabling deficit + onset window]
F --> G[Check BP, anticoagulants, platelet/coagulation issues, major bleeding risks]
G --> H{Eligible?}
H -->|Yes| I[Give alteplase without unnecessary delay]
H -->|No| J[Alternative pathway: thrombectomy/supportive care]
I --> K[Post-thrombolysis monitoring and repeat imaging protocol]
Essential before/alongside decision
- Non-contrast CT head
- Capillary blood glucose
- Basic neurological assessment including severity / disabling nature
- BP measurement and repeated monitoring
- Anticoagulant history / medication history
- CBC and platelets where indicated and quickly available
- Coagulation profile when anticoagulant use/coagulopathy suspected
Often done in parallel
- CT angiography if thrombectomy pathway considered
- Renal function/electrolytes
- ECG
In a clearly eligible patient, do not delay alteplase for unnecessary tests if hemorrhage has been excluded and no specific lab concern is suspected.
For a patient-friendly overview, see the NIDDK page.
Interpretation Frameworks
Bedside alteplase decision frame
- Is this really an ischemic stroke?
- What is the exact onset or last-known-well time?
- Is the deficit disabling?
- Is hemorrhage excluded on CT?
- Is BP acceptable or can it be made acceptable safely?
- Any major bleeding contraindication or anticoagulant issue?
- Is thrombectomy also indicated?
Disabling vs non-disabling thinking
Differential Diagnosis
- Intracerebral hemorrhage
- TIA with complete recovery
- Post-ictal Todd paresis
- Hypoglycaemia
- Functional neurological disorder
- Migraine aura
- Brain tumor / subdural collection in selected cases
Management of Intravenous alteplase eligibility
Immediate decision-making steps
- Activate stroke pathway.
- Record exact symptom onset or last-known-well.
- Perform NIHSS/deficit assessment with focus on functional disability.
- Get urgent non-contrast CT.
- Check glucose and treat severe abnormality.
- Review BP, anticoagulants, recent bleeding/surgery, and other contraindications.
If eligible
- Administer IV alteplase according to protocol without avoidable delay.
- Monitor neurologic status, BP, and bleeding signs closely.
- Avoid routine antiplatelet/anticoagulant use immediately afterward until follow-up imaging/protocol allows.
- Continue thrombectomy pathway if large-vessel occlusion is present and patient qualifies.
If not eligible
- Consider mechanical thrombectomy if appropriate.
- Provide best medical therapy and stroke-unit care.
- Start secondary prevention once safe and indicated.
Complications of Intravenous alteplase eligibility
- Symptomatic intracranial hemorrhage
- Orolingual angioedema
- Systemic bleeding
- Reperfusion failure / no clinical improvement
- Hemorrhagic transformation
FCPS/MRCP Exam Pearls and Clinical Boxes
- First rule: exclude hemorrhage on CT.
- Second rule: know the time/last-known-well.
- Third rule: ask whether the deficit is disabling.
- BP and anticoagulant history are exam favorites because they often determine eligibility.
- Alteplase can be given in thrombectomy candidates if they also meet thrombolysis criteria and local protocol supports it.
- Treating before clear hemorrhage exclusion.
- Ignoring a disabling posterior circulation syndrome because NIHSS seems modest.
- Over-focusing on age while missing the more important bleeding-risk variables.
- Assuming rapidly improving symptoms automatically mean “no alteplase.”
- Delaying treatment for non-essential tests.
Must Not Miss Red Flags
- Sudden neurological worsening after alteplase
- Severe headache, vomiting, acute hypertension spike after treatment
- New reduced consciousness suggesting hemorrhage
- Orolingual swelling threatening airway
- Large-vessel occlusion needing urgent thrombectomy pathway even if alteplase is started
Practical Clinical Approach
- Confirm the diagnosis of Intravenous alteplase eligibility using history, examination, and basic investigations.
- Assess severity and identify urgent complications early.
- Look for the underlying cause instead of stopping at the syndrome label.
- Review medications, comorbidity burden, and referral needs.
Frequently Asked Questions About Intravenous alteplase eligibility
Can intravenous alteplase eligibility improve or be stabilized?
That depends on the cause and the stage of disease. Early recognition, risk-factor control, and prompt treatment of complications often improve outcomes and may slow progression substantially.
When should intravenous alteplase eligibility become urgent?
Urgent escalation is needed when severe complications, rapid deterioration, marked biochemical abnormalities, or major cardiorespiratory compromise appear.
Conclusion
Intravenous alteplase eligibility is a time-critical reperfusion decision in acute ischemic stroke. The exam framework is simple but strict: confirm an ischemic disabling deficit, determine time/last-known-well, exclude hemorrhage on CT, ensure BP and bleeding risk are acceptable, and treat promptly without unnecessary delay. The main feared complication is symptomatic intracranial hemorrhage, and thrombectomy assessment should occur in parallel when large-vessel occlusion is suspected. A structured bedside approach, early recognition of complications, and appropriate stroke-unit follow-up remain central to safe care.
Medical disclaimer: This article is for medical education and professional awareness. Clinical decisions should always be individualized according to the patient’s condition, local protocols, and specialist advice when necessary.